Bioinsecticides from Bacillus thuringiensis (Bt) are widely used around the world in biological control against larval stages of many insect species. Bt has been considered a biopesticide that is highly specific to different orders of insects, non-polluting and harmless to humans and other vertebrates, thus becoming a viable alternative for combating agricultural pests and insect vectors of diseases. The family of Bt δ-endotoxins are crystal-protein inclusions showing toxicity to insects’ midgut, causing cell lysis leading to starvation, septicemia and death. The aim of this study is to evaluate the genotoxic potential of recombinant Bt spore–crystals expressing Cry1Ia, Cry10Aa and Cry1Ba6 on peripheral erythrocyte cells of Oreochromisniloticus, through comet assay, micronucleus (MN) test and nuclear abnormalities (NA) analysis. Fish (n = 10/group) were exposed for 96 h at 107 spores 30 l−1, 108 spores 30 l−1 or 109 spores 30 l−1 of Bt spore–crystals. Cry1Ia showed a significant increase in comet cells at levels 1 and 2, but not at levels 3 and 4, so it was not mutagenic nor did it induce MN or NA. These three spore–crystals showed some fish toxicity at only the highest exposure level, which normally does not occur in the field.
Despite chemotherapy’s limitations and toxic effects, it remains the primary treatment for most patients with triple-negative breast cancer (TNBC), with or without immune checkpoint inhibitors. Although cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy have revolutionized luminal breast cancer treatment, CDK4/6is alone are largely ineffective in TNBC, even with functional retinoblastoma protein (pRB). Activation of the receptor activator of nuclear factor κB (RANK) pathway has been associated with poor prognosis in TNBC and with resistance to CDK4/6is in luminal breast cancer, effects that can be reversed by RANK ligand inhibitors (RANKLi). In this study, we analyzed the effect of RANK knockdown or RANKLi in the response of pRB-proficient TNBC to CDK4/6i in vitro. RANK + patient-derived xenograft and cell line–derived xenograft models were used to assess therapeutic efficacy of CDK4/6i + RANKLi in vivo. Two syngeneic models of TNBC and luminal breast cancer were used to portrait the main therapy-induced alterations in the tumor immune microenvironment. RANK knockdown or RANKLi sensitized pRB-proficient TNBC cells to CDK4/6i in vitro. The combination of palbociclib and RANKLi regressed or prevented tumor growth and metastasis in vivo, enhancing cell cycle arrest. Both CDK4/6i and RANKLi elicited an antitumor immune response, characterized by an increase in CD4+ and CD8+ T cells and a decrease in tumor-associated macrophages infiltrating the tumor microenvironment. These findings suggest that combining CDK4/6i and RANKLi could offer a new therapeutic strategy for pRB-proficient TNBC, holding potential immunomodulatory benefits across breast cancer subtypes.
Despite chemotherapy’s limitations and toxic effects, it remains the primary treatment for most patients with triple-negative breast cancer (TNBC), with or without immune checkpoint inhibitors. Although cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy have revolutionized luminal breast cancer treatment, CDK4/6is alone are largely ineffective in TNBC, even with functional retinoblastoma protein (pRB). Activation of the receptor activator of nuclear factor κB (RANK) pathway has been associated with poor prognosis in TNBC and with resistance to CDK4/6is in luminal breast cancer, effects that can be reversed by RANK ligand inhibitors (RANKLi). In this study, we analyzed the effect of RANK knockdown or RANKLi in the response of pRB-proficient TNBC to CDK4/6i in vitro. RANK + patient-derived xenograft and cell line–derived xenograft models were used to assess therapeutic efficacy of CDK4/6i + RANKLi in vivo. Two syngeneic models of TNBC and luminal breast cancer were used to portrait the main therapy-induced alterations in the tumor immune microenvironment. RANK knockdown or RANKLi sensitized pRB-proficient TNBC cells to CDK4/6i in vitro. The combination of palbociclib and RANKLi regressed or prevented tumor growth and metastasis in vivo, enhancing cell cycle arrest. Both CDK4/6i and RANKLi elicited an antitumor immune response, characterized by an increase in CD4+ and CD8+ T cells and a decrease in tumor-associated macrophages infiltrating the tumor microenvironment. These findings suggest that combining CDK4/6i and RANKLi could offer a new therapeutic strategy for pRB-proficient TNBC, holding potential immunomodulatory benefits across breast cancer subtypes.
Supplementary Figure 3 (related to Fig. 3). Palbociclib in combination with OPG-Fc decreases the growth of palbociclib-resistant tumors in vivo and induces an inflammatory response. A, Rank expression in murine BC cell lines retrieved from CCLE (n = 4). B, Proliferation of the indicated cell lines cultured in the presence of CDK4/6i for 7 days and in drug-free media for an additional 7 days, as measured by a clonogenic assay (n = 3-4 independent experiments). C, Tumor weight at sacrifice (n = 4-8 tumors). D, Quantification of TRAcP5b in mouse serum by ELISA (n = 3 samples/group). E, Mouse body weight during treatment (n = 4-5 animals). The results are presented as the means ± SEMs. *p < 0.05, **p < 0.01.
Differentially expressed genes (DEGs) between treated (OPG-Fc n = 2; Palbo n = 2; COMB n = 3) and untreated (Vehicle, n = 3) MDA-MB-231 xenografts, ranked according to Log2FC (log2>1 or <-1; FDR q value<0.1). (.xls file)